Recent Publications

• How can orphan drug manufacturers combine pricing and market access strategies with health economics to optimize pricing and market access?

  Heemstra H., Heeg B. and Botteman M. Next Generation Pharmaceutical. 2010; Q3; 92-93. Link to pdf. -  Orphan drugs

  ---

• Cost-Effectiveness of Long-Acting Risperidone in Sweden 

  Hensen M, Heeg B, Löthgren M, van Hout B. Applied Health Economics and Health Policy. 2010; 8(5): 327-341. -  Mental and Neurological

  ---

• Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections

  Logman JFS, Stephens J, Heeg B, Cappelleri SHJ, Nathwani D, Tice A, van Hout BA. Current Medical Research & Opinion. 2010; 26(7): 1565-1578. -  Other

  ---

• Leveraging Opportunities in Comparative Effectiveness Research

  Botteman, M. Next Generation Pharmaceutical.  2010;  Q3; link to pdf. -  Methodology

  ---

• Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model
  based on the CLARITY trial.

  Thurston SJ, Heeg B, de Charro F, van Hout B. Current Medical Research and Opinion. 2010;26(3):641-51. -  Cardiovascular

  ---